本文選題：骨肉瘤　切入點(diǎn)：肺轉(zhuǎn)移　出處：《中國腫瘤臨床》2017年10期 　論文類型：期刊論文

【摘要】：目的:通過回顧北京大學(xué)人民醫(yī)院骨與軟組織腫瘤中心十年以上的肢體骨肉瘤肺轉(zhuǎn)移的病例,對(duì)其預(yù)后、治療過程進(jìn)行總結(jié),以期發(fā)現(xiàn)三氧化二砷(arsenic trioxide,ATO)聯(lián)合一線化療藥物對(duì)早期肺轉(zhuǎn)移病例的療效。方法:回顧性分析北京大學(xué)人民醫(yī)院骨腫瘤科自1998年3月至2014年12月收治的肢體骨肉瘤肺轉(zhuǎn)移的連續(xù)病例,挑選出治療過程中出現(xiàn)早期肺轉(zhuǎn)移及初治肺轉(zhuǎn)移曾經(jīng)使用過ATO長(zhǎng)期輸液聯(lián)合一線化療藥物(阿霉素、順鉑、大劑量氨甲喋呤和異環(huán)磷酰胺)進(jìn)行治療的病例。共計(jì)119例符合本研究條件,65例為初治肺轉(zhuǎn)移,54例為治療過程中發(fā)現(xiàn)肺轉(zhuǎn)移。結(jié)果:該組的病例經(jīng)治療,2年及5年總生存率分別為52.6%和30.9%。雖然僅20例接受了肺部切除手術(shù)(16.8%),但本中心選擇治療后的病例5年總生存情況和國際上其他區(qū)域的的生存情況類似(意大利Rizzoli的5年生存率為37%)。通過比較各項(xiàng)臨床病理學(xué)因素,發(fā)現(xiàn)骨轉(zhuǎn)移、雙側(cè)肺轉(zhuǎn)移、出現(xiàn)≥3個(gè)肺轉(zhuǎn)移結(jié)節(jié)以及不完全切除肺內(nèi)病灶,提示患者預(yù)后不佳。結(jié)論:ATO合并一線化療可能是一種有效且患者可耐受的新的治療選擇。肺切除手術(shù)應(yīng)該嚴(yán)格挑選合適的病例,以獲得最大的臨床受益。
[Abstract]:Objective: to review the prognosis and treatment process of osteosarcoma and lung metastasis of extremities in the center of bone and soft tissue tumor of people's Hospital of Peking University for more than ten years. In order to find out the curative effect of arsenic trioxide combined with first line chemotherapeutic drugs in the treatment of early lung metastasis. Methods: retrospective analysis was made on the treatment of limb osteosarcoma in the department of bone oncology, people's hospital of Peking university from March 1998 to December 2014. Consecutive cases of metastasis, Select early lung metastases and primary lung metastases that have been treated with ATO long-term infusion plus first-line chemotherapeutic drugs (adriamycin, cisplatin, cisplatin, adriamycin, cisplatin). Large doses of methotrexate and isocyclophosphamide). A total of 119 patients met the conditions in this study. 65 patients with primary lung metastasis were found in the course of treatment. Results: patients in this group were treated for 2 years and 5. The total annual survival rates were 52.6% and 30.90.Although only 20 patients underwent pulmonary resection, the overall survival of the patients selected by our center was similar to that in other regions of the world (5-year old in Rizzoli, Italy). The survival rate was 37%. By comparing various clinicopathological factors, Bone metastasis, bilateral lung metastasis, 鈮，

本文編號(hào)：1601726